[CAS NO. 7491-74-9]  Piracetam

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [7491-74-9]

Catalog
SLK-S3070
Brand
Selleck
CAS
7491-74-9

DESCRIPTION [7491-74-9]

Overview

MDLMFCD00079246
Molecular Weight142.16
Molecular FormulaC6H10N2O2
SMILESC(C(N)=O)N1C(=O)CCC1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Description

Piracetam (UCB 6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders.

Targets

AMPA receptor [1]

In vitro

Piracetam is able to significantly decrease the fusogenic and destabilising effect of Abeta 29-42, in a concentration-dependent manner. Preincubation of piracetam, at a piracetam/peptide ratio of 960, during 20 min before the addition of Abeta 29-42 prevents almost completely the mixture of the two fluorescent probes. Preincubation of piracetam with lipids prevents almost completely the release of calcein induced by the peptide in a dose-dependent fashion (piracetam/peptide ratios from 9.6 to 960). Piracetam (< 1.0 mM) preincubated with brain membranes enhances membrane fluidity in aged mice, rats and humans, as indicated by decreased anisotropy of the membrane-bound fluorescence probe 1,6-diphenyl-1,3,5-hexatriene (DPH).

In vivo

Piracetam (300 mg/kg once daily) significantly increases membrane fluidity in some brain regions of young and aged rats, but has no measurable effect on membrane fluidity in the young rats. Piracetam (300 mg/kg daily for 6 weeks) improves active avoidance learning in the aged rats only and elevates membrane fluidity in all brain regions except the cerebellum in the aged rats. Piracetam (300 mg/kg daily for 6 weeks) also improves NMDA receptor density in the hippocampus and on muscarinic cholinergic receptor densities in the frontal cortex and the striatum and to a lesser extent in the hippocampus of rats. Piracetam (500 mg/kg p.o. for 14 days) elevates N-methyl-D-aspartate (NMDA) receptor density by about 20% and normalizes the enhanced affinity of L-glutamate for the NMDA receptor in aged mice. Piracetam-treated withdrawn rats has higher the number of synapses than that observed in nonpiracetam-treated and alcohol-fed animals by up to 20%, the mechanisms leading to the synaptic reorganization took place at the mossy fiber level.


Synonyms

1-Pyrrolidineacetamide, 2-oxo-
2-Oxo-1-pyrrolidineacetamide
UCB 6215
Piracetam
Nootropil
2-Pyrrolidoneacetamide
2-Pyrrolidinoneacetamide
Euvifor
Nootropyl
Pirazetam
2-Oxo-1-pyrrolidinylacetamide
Pyracetam
Normabrain
Pyramem
Piramem
Prima
(2-Oxopyrrolidino)acetamide
2-Ketopyrrolidine-1-acetamide
Prima (pharmaceutical)
Myocalm
Gabacet
Nootrop
Geram
Nootron
Avigilen
Encetrop
Pirroxil
Cl 781
Axonyl
Norzetam
Genogris
Cerebroforte
Nootobril
Nootobryl
2-(2-Oxopyrrolidin-1-yl)acetamide
Neuracetam